Find clinical trials for Non-Small-Cell Lung Cancer in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma

Lung Cancer

Colorectal Cancer

Cancer

Neoplasm Metastasis

Squamous Cell Carcinoma of Head and Neck

Melanoma

Non-Small-Cell Lung Cancer trials near Charlotte, NC, USA:

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting

Non-Small Cell Lung Cancer Metastatic

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

Drug: Patritumab Deruxtecan (Fixed dose)

Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo

Charlotte, North Carolina, United States and 123 other locations

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying E...

Enrolling

Non-Small Cell Lung Cancer

EGFR/HER2 Exon 20 Insertion Mutation

Drug: STX-721/PFL-721 with platinum-based chemotherapy

Drug: STX-721/PFL-721 (Escalated) with platinum-based chemotherapy

Phase 1, Phase 2

Pierre Fabre

Charlotte, North Carolina, United States and 31 other locations

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. ...

Active, not recruiting

Lung Cancer, Non-squamous, Non-small Cell

Drug: carboplatin

Drug: zongertinib

Phase 3

Boehringer Ingelheim

Rock Hill, South Carolina, United States and 162 other locations

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

(SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung...

Active, not recruiting

Non-Small Cell Lung Cancer

Biological: Sacituzumab Govitecan-hziy (SG)

Drug: Docetaxel

Phase 3

Gilead Sciences

Charlotte, North Carolina, United States and 227 other locations

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

This is a single-arm, single-stage Phase II study designed to evaluate the 1-year PFS rate in subjects with locally-advanced NSCLC (stage II/III) and...

Active, not recruiting

Non Small Cell Lung Cancer

Lung Cancer Stage III

Drug: Paclitaxel

Drug: Durvalumab

Phase 2

Wake Forest University (WFU)

Charlotte, North Carolina, United States

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or...

Active, not recruiting

Recurrent Lung Non-Small Cell Carcinoma

Stage IV Lung Cancer AJCC v8

Biological: Pembrolizumab

Biological: Ramucirumab

Phase 3

SWOG Cancer Research Network

Charlotte, North Carolina, United States and 566 other locations

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, loca...

Enrolling

Non-Small Cell Lung Cancer

Drug: Cisplatin

Drug: Iza-bren

Phase 3

Bristol-Myers Squibb (BMS)

Charlotte, North Carolina, United States and 203 other locations

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel a-...

Enrolling

Recurrent Lung Non-Small Cell Carcinoma

Stage IV Lung Cancer AJCC v8

Drug: Docetaxel

Procedure: Biospecimen Collection

Phase 2, Phase 3

SWOG Cancer Research Network

Gaffney, South Carolina, United States and 412 other locations

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The pr...

Active, not recruiting

Non-small Cell Lung Cancer

Other: Placebo

Biological: Intismeran autogene

Phase 3

Merck Sharp & Dohme (MSD)

Charlotte, North Carolina, United States and 229 other locations

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with l...

Active, not recruiting

Advanced or Metastatic Non-Small Cell Lung Cancer

Drug: Durvalumab

Drug: Ceralasertib

Phase 3

AstraZeneca

Charlotte, North Carolina, United States and 190 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Non-Small-Cell Lung Cancer in .css-epvm6{white-space:nowrap;}Charlotte, NC

Related conditions:

Non-Small-Cell Lung Cancer trials near Charlotte, NC, USA:

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (EVOKE-01)

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002)

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Find clinical trials for Non-Small-Cell Lung Cancer in Charlotte, NC